Written questions by McVey.

Whether his Department holds information on how many Care Quality Commission inspections of (a) hospitals, (b) nursing and care homes, (c) GP practices, (d) dentists, (e) hospitals and (f) local authorities took place (i) in person and (ii) remotely in each of the last three years.

The table attached shows how many Care Quality Commission inspections of hospitals, dental practices, general practices, nursing and residential care homes, and local authorities took place from 2023 to the year to date in 2026. The data cannot accurately be broken down by ‘in person’ or ‘remotely’ so figures may combine both types of regulatory activity.

If the Government will introduce secondary legislation building on section 95 of the Health and Care Act 2022 to mandate the disclosure of payments made by the medicines and medical devices industries to the healthcare sector.

The Government recognises the importance of transparency and public trust in the health system. In line with Recommendation 8b of the Independent Medicines and Medical Devices Safety Review, the Government consulted in 2023 on proposals to improve transparency of payments made by the medicines and medical devices industries to the healthcare sector.Following consideration of the consultation responses, the Government has decided to implement guidance, rather than introduce secondary legislation under section 95 of the Health and Care Act 2022, in the first instance. The forthcoming guidance, which is expected to be published this year, will set out how and where payment information should be disclosed to ensure it is publicly accessible. Legislation remains an option for the future.

Where data on payments made by the medicines and medical devices industries to the healthcare sector will be published, following the publication of the Government’s forthcoming guidance on payment disclosure for industry.

The Government recognises the importance of transparency and public trust in the health system. In line with Recommendation 8b of the Independent Medicines and Medical Devices Safety Review, the Government consulted in 2023 on proposals to improve transparency of payments made by the medicines and medical devices industries to the healthcare sector.Following consideration of the consultation responses, the Government has decided to implement guidance, rather than introduce secondary legislation under section 95 of the Health and Care Act 2022, in the first instance. The forthcoming guidance, which is expected to be published this year, will set out how and where payment information should be disclosed to ensure it is publicly accessible. Legislation remains an option for the future.

If he will publish the toxicology non-clinical studies for zapomeran, also called Kostaive, mRNA covid-19 vaccine following its approval for adults by the Medicines and Healthcare products Regulatory Agency.

Whilst the Medicines and Healthcare products Regulatory Agency (MHRA) does not publish non-clinical studies, in line with Section 64 of the Human Medicines Regulations 2012, the MHRA has published a public assessment report (PAR) for Kostaive. This PAR includes the MHRA’s assessment of the non-clinical data submitted. This PAR is accessible to the public on the MHRA’s products website at the following link:https://mhraproducts4853.blob.core.windows.net/docs/0e710f66d3e04b6346f668178c02524de9248f57This product was authorised via the International Recognition Procedure ‘Route B’ process, with the European Medicines Agency (EMA) acting as the reference regulator. Further information on the EMA’s assessment of Kostaive, including its own PAR, is accessible to the public on the EMA’s website at the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/kostaive

Pursuant to the Answer of 23 February 2026 to Question 113069 on Folic Acid, what steps will be taken to stop wholemeal flour and other non-wheat products being voluntarily fortified with folic acid.

The Government introduced legislation in England on 14 November 2024 to mandate the fortification of non-wholemeal wheat flour with folic acid based on strong scientific assessment and modelling. The policy is estimated to prevent approximately 200 babies being born with neural tube defects each year.Voluntary fortification of other foods with folic acid has existed for many years, mainly in products such as breakfast cereals and the Government has no plans to restrict it.The fortification level for non-wholemeal flour was set using extensive modelling that accounted for existing voluntary fortification. This work showed that voluntary fortification makes only a small contribution to the number of people exceeding the recommended upper level for folic acid intake. On this basis, introducing limits on voluntary fortification was not considered necessary and would add regulatory complexity for businesses.The level of folic acid fortification will be kept under review as part of the evaluation of this policy.

Pursuant to the Answer of 18 December 2025 to question 98754, what his planned timetable is for publication of the packaging change report.

The Medicines and Healthcare products Regulatory Agency (MHRA) published an overview of the completion of the work by the expert working group (EWG) and subsequent advice from the Commission on Human Medicines (CHM) in December 2025 on the MHRA website. The MHRA has been working with healthcare partner organisations to take forward the recommendations of the EWG and the advice of the CHM. This includes seeking the views of patients with a range of mental health conditions on the proposed updates to the regulatory position for the 28 antidepressants involved in the review in relation to the warnings on suicidal behaviour. The MHRA is ensuring that those who take part receive appropriate safeguarding and signposting, which is required to support their involvement in this work. It is estimated that this user testing will be completed within three months. It is not possible to confirm the timetable for the publication of the public assessment report until the regulatory position is finalised.

What the average cost was of an inquiry into (a) NHS trust and (b) care trusts in the last 12 months.

There were three statutory and non-statutory inquiries into National Health Service trusts and care trusts commissioned by the Department in the 2025/26 financial year. The average cost per inquiry over this period is approximately £4.3 million.

What the annual budget for each individual NHS care trust was in each of the last five years.

The trust accounts consolidation data publications for National Health Service trusts and NHS foundation trusts include total operating income and expenditure, and are available for the last five financial years. Data for 2024/25 is currently being finalised for publication. This information is publicly available at the following link:https://www.england.nhs.uk/financial-accounting-and-reporting/nhs-providers-tac-data-publications/NHS England does not set annual budgets for individual trusts. Trusts earn income from their NHS commissioners for the clinical services they provide, as well as local authorities, private patient work, research, and other sources such as car parking. Trusts submit financial plans to NHS England for agreement that will reflect their planned income and expenditure, and performance against the plan is then monitored through the course of the financial year.

What estimate he has made of the number of mental health patients per caseworker across the country.

The information is not held in the format requested.

What the bed capacity was in each NHS care trust in each of the last five years.

NHS England publishes data on general and acute bed occupancy and capacity. The data can be found at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/bed-availability-and-occupancy/

Pursuant to the Answer of 13 February 2026 to Question 111118 on Coronavirus: Research, what is the definition of the word “routine” in this context.

In the context of the answer to Question 111118 of 13 February 2026, “routine” refers to the Prescription Medicines Code of Practice Authority standard practice on publications of audit outcomes.

With reference to The Bread and Flour (Amendment) (England) Regulations 2024, what steps he has taken to avoid harm to people unable to take folic acid.

The Government laid legislation in England on 14 November 2024 to introduce the mandatory fortification of non-wholemeal wheat flour with folic acid. Similar legislation in Scotland, Wales, and Northern Ireland has also been laid. The provisions will become mandatory in December 2026.Non-wholemeal wheat flour is already the established vehicle for mandatory fortification, as it is currently fortified with calcium, iron, niacin, and thiamine. There was a United Kingdom-wide agreement to limit folic acid fortification to flour that is already fortified, so that individuals are able to avoid fortified flour if they choose to or need to. These individuals will continue to be able to consume wholemeal flour and other non-wheat products, including gluten-free products and soy and spelt flours.To ensure people can easily identify products that are suitable for them, added vitamins and minerals, including folic acid, must be labelled in the flour’s ingredients list. This must also be declared when fortified flour is used as an ingredient. For individuals with specific dietary needs, personalised advice from a registered dietitian or healthcare professional is recommended to help manage intakes as part of a healthy, balanced diet. An impact assessment has been published alongside the legislation, and is available at the following link: https://www.legislation.gov.uk/uksi/2024/1162/resources

Pursuant to the Answer of 4 February 2026 to Question 109089 on Coronavirus: Research, when the UK Health Security Agency requested the report.

Routine audit outcomes by the Prescription Medicines Code of Practice Authority are not generally published or otherwise required to be shared externally beyond the parties involved. The UK Health Security Agency (UKHSA) requested this report from Moderna in January. Whilst this has yet to be received, the UKHSA is due to meet with Moderna in the coming weeks to further understand how they are considering the findings, beyond the responses they have already provided as part of the interim case report.Once the follow-up audit has concluded, expected in late 2026 or early 2027, the final case report and any associated outcomes will be published in accordance with the Association of the British Pharmaceutical Industry Code of Practice.

Pursuant to the Answer of 26 January 2026 to Question 106102 on Coronavirus: Research, for what reason they have yet to receive a copy of the audit; and how the scope of the recommendations can be understood without it.

The UK Health Security Agency has requested this report and continues discussions with Moderna on their response to the audit’s recommendations. This is being considered and reviewed alongside the commercial management of the Moderna-United Kingdom Strategic Partnership.

Pursuant to the Answer of 23 June 2025 to Question 59379 on Coronavirus: Research, and with reference to FOI 15/11/25/IR/575, when the UKHSA expects to receive the report from (a) Moderna and (b) PMCPA to review.

The UK Health Security Agency (UKHSA) has yet to receive a copy of the Prescription Medicines Code of Practice Authority (PMCPA) audit report. However, as part of the United Kingdom’s Strategic Partnership with Moderna, the UKHSA is working to understand the scope of the audit's recommendations and how Moderna is addressing them. This includes any corrective actions they are putting in place ahead of a further audit, which the PMCPA have indicated they will carry out in late 2026, early 2027.

Pursuant to the Answer 1 December 2025 to Question HL12274 on Visual Snow Syndrome: Yellow Card Scheme, if he will confirm whether official UK drug labels or patient information leaflets warn about the possibility of this condition occurring.

Visual snow syndrome (VSS) was officially recognized in 2025 with a unique code in the eleventh edition of the International Classification of Diseases by the World Health Organization. Very few cases of VSS have been reported with 22 individual drugs or vaccines through the Yellow Card scheme.VSS is a rare disorder and the underlying cause currently unknown. The Medicines and Healthcare products Regulatory Agency (MHRA) keeps all licensed medicines and vaccines under close monitoring and any potential signal of an association between a medicine or vaccine exposure and development of VSS will be rigorously assessed through the MHRA’s multidisciplinary signal review process and added to individual product information when there is data available to support regulatory action.

Pursuant to the answer of 4 July 2025 to question 63299, when he plans to publish the report on packaging changes to Selective serotonin reuptake inhibitors, as discussed at the Commission on Human Medicines Antidepressant Risk Minimisation Expert Working Group on 1 May.

The Commission on Human Medicines Antidepressant Risk Minimisation Expert Working Group met in May and July 2025 and their recommendations were subsequently considered by the Commission on Human Medicines in September 2025. A public assessment report summarising the data considered and the recommendations will be published by the Medicines and Healthcare products Regulatory Agency (MHRA) as soon as the regulatory position is finalised with the 105 marketing authorisation holders of the 28 antidepressants involved in the review. An exact date for publication of the public assessment report cannot be confirmed yet. The MHRA will issue a Drug Safety Update to inform healthcare professionals in the United Kingdom of the new regulatory position for all antidepressants, not only selective serotonin reuptake inhibitors, and publication of the public assessment report.

Pursuant to the Answer of 7 July 2025 to Question 64393 on Vaccine Damage Payment Scheme: Coronavirus, what steps he is taking to improve the Vaccine Damage Payment Scheme.

I would like to reiterate my profound and sincere sympathies to all those individuals who have experienced harm following vaccination, and to their families.The Department has been working with the NHS Business Services Authority (NHSBSA), the administrators of the Vaccine Damage Payment Scheme (VDPS), to take steps to improve the scheme and process claims at a faster rate. Building on work to scale up and modernise operations through the digitisation of the claims process and increasing administrative staff working on the VDPS, the NHSBSA is engaging with healthcare providers to improve the return rate of medical records, essential to assessing claims, including through submitting subject access requests.In parallel, Ministers continue to actively consider a range of options for further reforming the VDPS.

With reference to FOI request 24/015 to the Medicines and Healthcare products Regulatory Agency, if he will publish the responses received from the Swedish Medical Products Agency following their offer to contact (a) children and (b) teenager psychiatrists.

The Medicines and Healthcare products Regulatory Agency have confirmed that the response received from the Swedish Medical Products Agency in relation to the 2008 assessment of preclinical data published within FOI 24/015 did not contain an offer to contact psychiatrists responsible for the care of children and teenagers.

How much funding his department allocated to the indemnity schemes in place for Covid-19 vaccinations.

We are unable to provide full information as requested regarding the valuation of the COVID-19 vaccine indemnities due to their commercial sensitivity.The existence of the COVID-19 vaccination indemnities is disclosed in the contingent liabilities note within the Department’s group annual report and accounts (ARA). The value of the contingent liabilities was not disclosed due to their sensitive nature. There is also a provision for a COVID-19 vaccination indemnity included in the ARA as part of ‘other’ in the provisions note.The most recently published ARA is available at the following link:https://assets.publishing.service.gov.uk/media/676150ef26a2d1ff18253415/dhsc-annual-report-and-accounts-2023-2024-web-accessible.pdf